ERBB2 and breast cancer: Therefore, simultaneous pharmacological targeting of crucial metabolic pathways with a combination of targeted agents, as in other types of co-administration clinical models, could prevent or delay the onset of resistance phenomena and possibly contribute to liver safety events in HER2+ BC patients.